Astria Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Astria Therapeutics, Inc. carries a market capitalization of 718.13M, placing it among publicly traded companies globally. Its enterprise value stands at 294.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 718.13M |
| Enterprise Value | 294.34M |
Share Statistics
Astria Therapeutics, Inc. currently has 56.43M shares outstanding.
| Shares Outstanding | 56.43M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 598.13, and the price-to-book ratio stands at -0.55.
| PE Ratio | N/A |
| PS Ratio | 598.13 |
| PB Ratio | -0.55 |
| P/TBV Ratio | 3.06 |
| P/FCF Ratio | -3.53 |
| P/OCF Ratio | -3.53 |
Enterprise Valuation
| EV / Sales | 416.92 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Astria Therapeutics, Inc. maintains a current ratio of 10.78, meaning it holds 10.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.78 |
| Quick Ratio | 10.42 |
| Debt / Equity | 1.91 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Astria Therapeutics, Inc.'s stock has gained approximately 92.64931% over the past 52 weeks. The 50-day moving average sits at 12.74, while the 200-day moving average is 8.32.
| Beta (5Y) | N/A |
| 52-Week Price Change | 92.64931% |
| 50-Day Moving Average | 12.74 |
| 200-Day Moving Average | 8.32 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Astria Therapeutics, Inc. generated 706,000.00 in revenue and converted that into -124.03M in net income, yielding earnings per share of -2.14. EBITDA reached -136.51M, while operating income came in at -136.51M.
| Revenue | 706,000.00 |
| Gross Profit | N/A |
| Operating Income | -136.51M |
| Pretax Income | -124.03M |
| Net Income | -124.03M |
| EBITDA | -136.51M |
| EBIT | -136.51M |
| Earnings Per Share (EPS) | -2.14 |
Balance Sheet
Astria Therapeutics, Inc. holds 227.72M in cash and equivalents against 4.46M in total debt, resulting in a net debt position of -96.28M. Total book value stands at -773.14M, with working capital of 230.03M providing operational flexibility.
| Cash & Cash Equivalents | 227.72M |
| Total Debt | 4.46M |
| Net Debt | -96.28M |
| Equity (Book Value) | -773.14M |
| Book Value Per Share | -13.33 |
| Working Capital | 230.03M |
Cash Flow
Astria Therapeutics, Inc. produced -119.73M in operating cash flow over the past twelve months.
| Operating Cash Flow | -119.73M |
| Capital Expenditures | N/A |
| Free Cash Flow | -119.73M |
| FCF Per Share | -2.06 |
Margins
Astria Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -19,335.69 and net profit margin of -17,567.99 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -19,335.69 |
| Pretax Margin | -17,567.99 |
| Profit Margin | -17,567.99 |
| EBITDA Margin | -19,335.69 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.00 |
| FCF Yield | -28.35 |
Stock Splits
Astria Therapeutics, Inc.'s most recent stock split took place on August 20, 2021 with a 6:1 split ratio.
| Last Split Date | 8/20/2021 |
| Split Ratio | 6:1 |
Scores
Astria Therapeutics, Inc. posts an Altman Z-Score of 1.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.94 |